Retrophin
As of the edition of 20 October 2026, Retrophin runs 5 drugs, 3 of them marketed; it is on route A at 0 targets and on route B at 1 target.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Family history
Retrophin was renamed in 2020.
- RETROPHIN, INC.: renamed in 2020
Drugs by status
| Status | Count |
|---|---|
| Marketed | 3 |
| Active | 1 |
| Stopped | 1 |
| Total | 5 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Oxytocin | none listed | 1 |
| Sparsentan | Ends 2031 (exclusivity) | 2 |
| Cholic acid | none listed | 0 |
A route B row is one company at one target.
Where it needs a new molecule
Route A at 0 targets, route B at 1 target.
| Target | Route |
|---|---|
| AGTR1 Type-1 angiotensin II receptor | Route B |
All 1 row on route A or B
In the product1 company-target row on route A or B; 0 are not shown here, and no score is.
See all 1 targets where Retrophin needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.
Where its trials are
- Pregnancy and women's health: 7 trials led
- Urinary and reproductive: 7 trials led
- Inherited and neonatal: 5 trials led